股票 
板块 
用户 
资讯 展会背景Exhibition BackgroundCPHI Milan 2026（世界制药原料展览会）将于2026年10月6日至8日在意大利米兰Fiera Milano举行。作为全球制药行业重要的专业交流与合作平台，CPHI汇聚来自全球制药产业链的供应商、创新企业及行业专业人士，致力于促进产业交流、技术创新、供应链合作与全球业务拓展。根据官方公布的2025年数据，CPHI吸引了约62,000名专业观众、2,900余家参展企业，覆盖166个以上国家和地区，体现了其广泛的国际影响力。本届展会覆盖原料药（APIs）、生物生产、合同服务、CRO、药用辅料、精细化学品、制剂、制药机械与设备以及药品包装与递送等制药产业链核心领域，并于2026年进一步增设AI与技术、冷链与物流、污染控制及标签等专题展区。同期会议将围绕人工智能与技术、生物制造、研发、生产制造、供应链、监管政策、包装与药物递送及可持续发展等议题展开，由250余位行业专家分享产业趋势与实践经验。通过展览展示、专业论坛及商务交流等多种形式，CPHI Milan 2026将为全球医药企业洞察行业趋势、链接国际产业资源、拓展合作伙伴及探索创新发展机遇提供重要平台。CPHI Milan 2026 will take place from 6–8 October 2026 at Fiera Milano, Italy. As a major international platform for the pharmaceutical industry, CPHI brings together suppliers, innovators and professionals from across the global pharmaceutical value chain, facilitating industry exchange, technological innovation, supply-chain collaboration and international business development. According to official figures for the 2025 edition, the event welcomed approximately 62,000 attendees and more than 2,900 exhibiting companies, with representation from over 166 countries, demonstrating its extensive global reach and industry influence.CPHI Milan 2026 will cover key sectors across the pharmaceutical supply chain, including APIs, bioproduction, contract services, CRO, excipients, fine chemicals, finished dosage forms, pharmaceutical machinery and equipment, and packaging and drug delivery. New zones for 2026 will further focus on AI & Tech, Cold Chain & Logistics, Contamination Control and Labelling. The conference programme will feature more than 250 expert speakers addressing topics such as AI and technology, biomanufacturing, R&D, manufacturing, supply chains, regulation and policy, packaging and drug delivery, and sustainability. Through exhibitions, expert-led content and business networking, CPHI Milan 2026 provides a key platform for pharmaceutical companies to explore emerging industry trends, connect with global resources and partners, and identify new opportunities for innovation and international collaboration.
赛默制药简介About Zhejiang CDMO Pharmaceutical浙江赛默制药有限公司是一家专业提供CDMO/CMO服务的平台型企业，为杭州百诚医药科技股份有限公司（301096.SZ）全资子公司。公司聚焦原料药、制剂成品及技术转移与产业化，为客户提供涵盖技术研发、工艺放大、产品转化、工艺验证、质量研究、注册申报及商业化生产的一体化服务。公司已建成约14万平方米GMP标准厂房及配套实验室，拥有100余条原料药及制剂生产线，覆盖口服固体、口服液体、注射液、滴眼液、吸入溶液、外用制剂及原料药等25个剂型。截至2026年4月底，公司已与232家医药企业开展合作，累计完成619个验证项目，其中制剂516个、原料药103个；263个制剂项目获批，50个原料药品种获批转A，并已实现130个制剂项目和32个原料药项目商业化生产。在国际注册方面，公司已有3个原料药品种申报欧盟注册并取得3个CEP证书。依托经验丰富的生产、技术及质量管理团队，赛默制药致力于为全球合作伙伴提供从API到制剂、从技术转移到规模化生产、从注册申报到商业化落地的高效、可靠CDMO/CMO解决方案，加速药品从研发走向市场。Zhejiang CDMO Pharmaceutical is a platform-based enterprise specializing in CDMO/CMO services and is a wholly-owned subsidiary of Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (Stock Code: 301096.SZ). The company focuses on Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), and technology transfer and commercial manufacturing, providing clients with integrated services covering technology R&D, process scale-up, product transformation, process validation, quality studies, regulatory submissions, and commercial production.Zhejiang CDMO Pharmaceutical operates approximately 140,000 m2 of GMP-standard manufacturing facilities and laboratories, with more than 100 API and formulation production lines covering 25 dosage forms, including oral solids, oral liquids, injections, ophthalmic products, inhalation solutions, topical formulations and APIs. As of April 2026, Zhejiang CDMO Pharmaceutical had collaborated with 232 pharmaceutical companies and completed 619 validation projects, including 516 formulation projects and 103 API projects. A total of 263 formulation projects have been approved, 50 API products have obtained active registration status, while 130 formulation projects and 32 API projects have entered commercial production. In addition, three APIs have been submitted for EU registration, with three CEPs obtained.With integrated capabilities from API to FDF, technology transfer to scale-up, and regulatory filing to commercialization, Zhejiang CDMO Pharmaceutical is committed to providing efficient and reliable CDMO/CMO solutions for global pharmaceutical partners and accelerating the journey from development to market.
评论 (0)